Opportunity Information: Apply for RFA NS 24 018
The HEAL Initiative funding opportunity titled "Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)" (RFA-NS-24-018) is a National Institutes of Health (NIH) cooperative agreement designed to speed up the development of reliable, clinically useful pain biomarkers. The central aim is to identify and validate strong candidate biomarkers or multi-measure biomarker signatures (biosignatures) that can make Phase II testing of non-opioid pain treatments more efficient and informative. In practical terms, NIH is looking for clinical research programs that can produce objective measures that either predict who will respond to a given pain therapy and/or track whether a therapy is working over time, so that mid-stage trials can be run with better participant selection, clearer endpoints, and stronger interpretability.
The FOA is focused on biomarker discovery and biosignature development tied directly to therapeutic response, not just general pain characterization. Projects are expected to be structured around clinical research that links candidate measures to treatment effects, meaning applications should be built to evaluate whether a biomarker or signature can predict response (treatment selection or stratification) and/or monitor response (pharmacodynamic or longitudinal tracking) in the context of pain therapeutics. The end product NIH wants is a set of measures that can realistically be deployed in Phase II clinical trials of non-opioid pain therapeutics to improve decision-making about whether a therapy is working and for whom.
A key design feature is flexibility around pain conditions, paired with an expectation of rigor and standardization. Applicants may focus on a single pain condition or multiple pain conditions that share a common underlying biology or pathophysiology. For multi-condition proposals, the FOA strongly emphasizes Multiple Principal Investigator (MPI)-led teams that include leaders representing each pain condition and the relevant clinical networks. These teams are expected to agree on one harmonized set of measures or biomarker modalities to serve as the biosignature across all included conditions. The idea is to avoid siloed approaches where each condition uses different tools; instead, NIH is pushing for coordinated, comparable data and a unified signature that can generalize across related pain states.
The announcement explicitly encourages biosignatures built from one or more measurement modalities, reflecting how pain biology and treatment response may not be captured by a single test. Examples of modalities named in the FOA include omics-based measures (such as genomics, proteomics, metabolomics), quantitative sensory testing (QST), actigraphy, EEG, and digital measures, among others. The expectation is that applicants will justify why their selected modalities are appropriate for predicting or monitoring treatment response and how combining them (if proposing a multi-modal signature) improves performance, robustness, or clinical usability compared with any single measure alone.
To make results credible and reusable across sites and conditions, the FOA expects applications to include centralized resource groups. These centralized components are intended to coordinate clinical trial-related activities and enforce consistency across the program, including standardized sample and data collection methods, technology development, statistical analysis plans, and algorithm development. In multi-condition projects, these centralized resources are especially important because they ensure that data generated across different condition cohorts can be pooled or compared without being undermined by inconsistent procedures, instrumentation differences, or variable analytic pipelines. For single-condition projects, the same centralized approach is still expected, serving to professionalize and unify the operational, technical, and analytic work so the biomarker or biosignature is built on reproducible foundations.
Even when the project is limited to one pain condition, NIH is still looking for MPI-led teams, but the rationale shifts slightly: the MPI structure should reflect cross-functional expertise needed for biomarker or biosignature development. That typically means combining clinical pain expertise with complementary strengths such as biostatistics, computational modeling and machine learning for signature development, assay development or bioinformatics for omics, neurophysiology for EEG-based measures, digital health analytics for wearable or smartphone-derived metrics, and clinical trial operations for implementation. The overarching message is that biomarker development is multidisciplinary by necessity, and NIH wants teams organized to handle that complexity from the start rather than bolting on key expertise later.
From an administrative standpoint, the opportunity is offered as a cooperative agreement under the UG3/UH3 mechanism, and it is labeled "Clinical Trial Optional." Cooperative agreements generally imply substantial NIH programmatic involvement compared with standard grants, often including active coordination, milestone oversight, and collaborative expectations. The UG3/UH3 structure commonly supports a phased project, where an initial stage supports planning, set-up, and early feasibility work, with progression to the later stage tied to meeting predefined milestones. While specific milestone language is not included in the provided excerpt, applicants should expect that the program will be managed with go/no-go decision points consistent with a phased cooperative agreement model.
Eligibility is broad and includes many kinds of organizations that can support clinical research, technology development, and multi-site coordination. Eligible applicants listed in the source include state, county, and municipal governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and other entities. The FOA also highlights additional eligible categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, non-U.S. (foreign) entities, and U.S. territories or possessions. This breadth is consistent with the HEAL Initiative's emphasis on building capable, diverse consortia and ensuring that expertise and participant populations can be drawn from many settings.
In summary, this HEAL Initiative FOA is aimed at producing actionable pain biomarkers or biomarker signatures that directly support Phase II trials of non-opioid pain therapeutics. Successful applications are expected to be clinically grounded, multi-disciplinary, and operationally centralized, with harmonized measures and standardized methods that can stand up across sites and, when relevant, across multiple related pain conditions. The program is less about exploratory measurement for its own sake and more about delivering validated predictors and monitoring tools that make pain therapeutic trials faster, cleaner, and more likely to yield clear answers.Apply for RFA NS 24 018
- The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.233, 93.273, 93.394, 93.395, 93.396, 93.837, 93.838, 93.839, 93.840, 93.853, 93.865, 93.866, 93.867.
- This funding opportunity was created on 2023-02-15.
- Applicants must submit their applications by 2023-10-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) (RFA-NS-24-018)
1) What is the main goal of this HEAL Initiative funding opportunity?
The goal is to speed development of reliable, clinically useful pain biomarkers and multi-measure biomarker signatures (biosignatures) that can be used in Phase II clinical trials of non-opioid pain therapeutics. The focus is on identifying and validating objective measures that help trials run more efficiently and produce clearer, more interpretable results.
2) What kind of end product is NIH looking for?
NIH is looking for validated biomarkers or biosignatures that can realistically be deployed in Phase II trials to improve decision-making, including (a) predicting which participants are more likely to respond to a therapy and/or (b) monitoring whether a therapy is working over time.
3) Is this opportunity about general pain measurement or about treatment response?
It is specifically about biomarkers and biosignatures tied directly to therapeutic response. The intent is not just to characterize pain in general, but to connect candidate measures to treatment effects so they can support trial decisions.
4) What does NIH mean by a biomarker versus a biosignature?
Based on the description provided, a biomarker is a candidate objective measure that may relate to treatment response. A biosignature is a multi-measure signature that can combine one or more modalities into a stronger, more robust set of measures for predicting or monitoring response.
5) What trial-stage is this FOA trying to support?
The FOA is designed to make Phase II testing of non-opioid pain treatments more efficient and informative by improving participant selection, endpoints, and interpretability.
6) What are the two main use cases NIH highlights for these biomarkers?
NIH highlights two practical use cases: predicting response (to support treatment selection/stratification) and monitoring response (to track pharmacodynamic or longitudinal change during treatment).
7) Are applicants required to focus on a single pain condition?
No. Applicants may focus on a single pain condition or propose multiple pain conditions, particularly when the conditions share a common underlying biology or pathophysiology.
8) If a project includes multiple pain conditions, what does NIH expect?
For multi-condition proposals, the FOA strongly emphasizes Multiple Principal Investigator (MPI)-led teams that include leaders representing each pain condition and relevant clinical networks. NIH also expects the team to agree on one harmonized set of measures or biomarker modalities to serve as the biosignature across all included conditions.
9) Why does NIH emphasize harmonization across conditions and sites?
The FOA aims to avoid siloed approaches where each condition uses different tools. Harmonized measures and standardized methods are intended to support coordinated, comparable data that can be pooled or compared across cohorts and sites without being undermined by inconsistent procedures or analytic pipelines.
10) What kinds of measurement modalities are encouraged for biomarkers or biosignatures?
The FOA explicitly encourages biosignatures built from one or more modalities. Examples named include omics-based measures (genomics, proteomics, metabolomics), quantitative sensory testing (QST), actigraphy, EEG, and digital measures, among others.
11) Does NIH prefer single-modality biomarkers or multi-modal biosignatures?
The FOA encourages biosignatures that may combine modalities, reflecting that pain biology and treatment response may not be captured by a single test. Applicants are expected to justify why their chosen modalities are appropriate and, if combining them, how a multi-modal approach improves performance, robustness, or clinical usability compared with any single measure alone.
12) What is meant by “centralized resource groups,” and why are they important?
Centralized resource groups are program components intended to coordinate clinical trial-related activities and enforce consistency across the program. They are described as supporting standardized sample and data collection methods, technology development, statistical analysis plans, and algorithm development. Their purpose is to make results credible and reusable across sites and conditions.
13) Are centralized resources expected even for a single-condition project?
Yes. Even for a single-condition project, the FOA describes a centralized approach as expected to unify operational, technical, and analytic work so the biomarker or biosignature is built on reproducible foundations.
14) What team structure does NIH expect for single-condition projects?
Even when limited to one pain condition, NIH is still looking for MPI-led teams. In that context, the MPI structure is meant to reflect cross-functional expertise needed for biomarker or biosignature development.
15) What types of expertise are implied for MPI-led teams?
The FOA description points to multidisciplinary needs such as clinical pain expertise plus complementary strengths in biostatistics, computational modeling and machine learning (for signature development), assay development or bioinformatics (for omics), neurophysiology (for EEG-based measures), digital health analytics (for wearable or smartphone-derived metrics), and clinical trial operations (for implementation).
16) What funding mechanism is used for this opportunity?
This is an NIH cooperative agreement using the UG3/UH3 mechanism, and it is labeled “Clinical Trial Optional.”
17) What does it mean that this is a cooperative agreement?
Cooperative agreements generally involve substantial NIH programmatic involvement compared with standard grants. The description notes expectations such as active coordination, milestone oversight, and collaborative expectations.
18) What does UG3/UH3 imply about project structure?
The UG3/UH3 structure commonly supports a phased project, with an initial stage for planning, set-up, and early feasibility work, followed by a later stage. Progression is typically tied to meeting predefined milestones, with go/no-go decision points consistent with a phased cooperative agreement model.
19) Does this FOA require a clinical trial?
The FOA is labeled “Clinical Trial Optional,” indicating that a clinical trial is not necessarily required in every application under this opportunity, based on the information provided.
20) Who is eligible to apply?
Eligibility is broad and includes many organization types. The listed eligible applicants include state, county, and municipal governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses) as well as small businesses; and other entities.
21) Are minority-serving institutions and community-based organizations included in eligibility?
Yes. The FOA highlights eligible categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and faith-based or community-based organizations.
22) Can non-U.S. entities apply?
Yes. The eligibility list includes non-U.S. (foreign) entities, as well as U.S. territories or possessions.
23) What types of pain therapeutics is NIH targeting?
The FOA is centered on Phase II trials for non-opioid pain therapeutics, with biomarkers intended to improve how these trials identify responders and track treatment effects.
24) What makes an application aligned with NIH’s priorities in this FOA?
Based on the description, aligned applications are clinically grounded and directly link candidate biomarkers or biosignatures to treatment response. They emphasize rigor, standardization, and centralized coordination, and they are structured to produce measures that can be deployed in Phase II trials to improve participant selection, endpoints, and interpretability.
Browse more opportunities from the same category: Education, Health, Income Security and Social Services
Next opportunity: NIJ FY23 Research and Development in Forensic Science for Criminal Justice Purposes
Previous opportunity: Bureau of Land Management New Mexico Recreation and Visitor Services
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NS 24 018
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NS 24 018) also looked into and applied for these:
| Funding Opportunity |
|---|
| Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) Apply for PAR 23 131 Funding Number: PAR 23 131 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $225,000 |
| Understanding Chronic Conditions Understudied Among Women (R01 Clinical Trial Optional) Apply for RFA OD 23 014 Funding Number: RFA OD 23 014 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $350,000 |
| Understanding Chronic Conditions Understudied Among Women (R21 Clinical Trial Optional) Apply for RFA OD 23 013 Funding Number: RFA OD 23 013 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $275,000 |
| Entry-Level Modules (ELM) for Training the Genomics Research Workforce (R25-Clinical Trial Not Allowed) Apply for PAR 23 123 Funding Number: PAR 23 123 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $550,000 |
| BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) Apply for RFA NS 24 005 Funding Number: RFA NS 24 005 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) Apply for RFA NS 24 004 Funding Number: RFA NS 24 004 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Brain Behavior Quantification and Synchronization Data Coordination and Artificial Intelligence Center (U24 Clinical Trial Optional) Apply for RFA MH 23 130 Funding Number: RFA MH 23 130 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) Apply for RFA MH 23 110 Funding Number: RFA MH 23 110 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R61 Basic Experimental Studies with Humans Required) Apply for RFA DC 24 001 Funding Number: RFA DC 24 001 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) Apply for RFA MH 23 270 Funding Number: RFA MH 23 270 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed) Apply for RFA MH 23 331 Funding Number: RFA MH 23 331 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) Apply for RFA TR 23 010 Funding Number: RFA TR 23 010 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required) Apply for RFA MH 23 330 Funding Number: RFA MH 23 330 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed) Apply for RFA NS 23 026 Funding Number: RFA NS 23 026 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) Apply for PAR 23 161 Funding Number: PAR 23 161 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional) Apply for RFA NS 23 025 Funding Number: RFA NS 23 025 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Targeted BRAIN Circuits Planning Projects TargetedBCPP (R34 Clinical Trials Not Allowed) Apply for RFA NS 23 023 Funding Number: RFA NS 23 023 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $450,000 |
| BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed) Apply for RFA NS 23 024 Funding Number: RFA NS 23 024 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional) Apply for RFA MH 23 295 Funding Number: RFA MH 23 295 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) Apply for RFA MH 23 290 Funding Number: RFA MH 23 290 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NS 24 018", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.